GLUL抗体;GLUL Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using GLUL mouse mAb against Jurkat (1), and mouse liver (2) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of hela cells using GLUL mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using GLUL mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cerebellar tissues using GLUL mouse mAb with DAB staining.    

  
  

**Background of GLUL Antibody**

GLUL (glutamine synthetase) is a key enzyme encoded by the *GLUL* gene, responsible for catalyzing the ATP-dependent conversion of glutamate and ammonia into glutamine. This reaction is critical for nitrogen metabolism, neurotransmitter recycling, and maintaining cellular homeostasis. GLUL is highly expressed in the liver, brain (particularly in astrocytes), and kidneys, reflecting its role in detoxifying ammonia, supporting energy production, and modulating redox balance.

Antibodies targeting GLUL are widely used in research to study its expression, localization, and function in physiological and pathological contexts. In the central nervous system, GLUL is essential for the glutamate-glutamine cycle, which regulates excitatory neurotransmission. Dysregulation of GLUL has been implicated in neurodegenerative diseases (e.g., Alzheimer’s), hepatic encephalopathy, and cancer, where altered glutamine metabolism supports tumor growth.

GLUL antibodies are employed in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate tissue-specific expression patterns or changes under disease conditions. For example, in liver disease models, reduced GLUL levels may indicate impaired detoxification, while in gliomas, elevated expression correlates with aggressive tumor behavior.

Validation of GLUL antibodies is crucial, requiring specificity checks via knockout controls or siRNA-mediated silencing. Commercial antibodies often target conserved regions, such as the N-terminal domain, to ensure cross-reactivity in multiple species. As glutamine metabolism gains attention in therapeutic research, GLUL antibodies remain vital tools for unraveling metabolic dysregulation and identifying biomarkers or therapeutic targets.